One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA
Executive Summary
One year after the withdrawal of Vioxx, FDA appears to be rebalancing its focus from a heightened emphasis on safety towards a greater appreciation of the emerging efficacy of drugs
You may also be interested in...
FDA Inc.? Von Eschenbach Vows To Bring Corporate Practices To Agency
FDA Commissioner nominee Andrew von Eschenbach is committed to bringing corporate business practices to the agency if confirmed
FDA Inc.? Von Eschenbach Vows To Bring Corporate Practices To Agency
FDA Commissioner nominee Andrew von Eschenbach is committed to bringing corporate business practices to the agency if confirmed
Atrovent, Spiriva Safety To Be Tracked In Pharmacy Active Surveillance Pilot
An active drug surveillance system pilot, directed by the Critical Path Institute (C-Path), will track safety and efficacy information for the chronic obstructive pulmonary disorder therapies Atrovent and Spiriva